A5062147169- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Viral Infections and Vectors
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Virology and Viral Diseases
- Monoclonal and Polyclonal Antibodies Research
- Vaccine Coverage and Hesitancy
- Cancer-related molecular mechanisms research
- Hepatitis B Virus Studies
- SARS-CoV-2 detection and testing
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Platelet Disorders and Treatments
- HIV Research and Treatment
- MicroRNA in disease regulation
- COVID-19 epidemiological studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Respiratory viral infections research
- Environmental Conservation and Management
- Immune responses and vaccinations
Bernhard Nocht Institute for Tropical Medicine
2019-2025
University Medical Center Hamburg-Eppendorf
2015-2024
German Center for Infection Research
2015-2024
Universität Hamburg
2015-2024
Leibniz Institute of Virology (LIV)
2012-2018
Martini-Klinik
2015
Universitäts-Augenklinik Bonn
2010
RWTH Aachen University
1999-2003
Ophthalmology Clinic
1999
The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.We performed three open-label, dose-escalation phase 1 trials one randomized, double-blind, controlled trial to assess the safety, side-effect profile, of rVSV-ZEBOV at various doses 158 healthy adults Europe Africa. All participants were injected with ranging from...
The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a disease with case fatality rate of up to 35%. Given its potential cause public health emergency and the absence efficacious drugs or vaccines, MERS is one WHO priority diseases warranting urgent research development countermeasures. We aimed assess safety tolerability an anti-MERS-CoV modified vaccinia virus Ankara (MVA)-based vaccine candidate that expresses MERS-CoV spike glycoprotein, MVA-MERS-S, in healthy adults.
Predicting vaccine efficacy remains a challenge. We used systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes cytokine levels, cell subsets, gene expression. Integrative statistical analyses with cross-validation identified signature 5 markers correlating titers on day 28 beyond. Among those, IP-10 3 MFI CXCR6 NK cells 1 independent...
BackgroundThe recent West African Ebola epidemic led to accelerated efforts test vaccine candidates. As part of the World Health Organisation-led VSV Consortium (VEBCON), we performed a phase I clinical trial investigating rVSV-ZEBOV (a recombinant vesicular stomatitis virus-vectored vaccine), which has recently demonstrated protection from virus disease (EVD) in III trials and is currently advanced stages licensing. So far, correlates immune are incompletely understood role cell-mediated...
The human gammaherpesvirus Kaposi sarcoma-associated herpesvirus is strongly linked to neoplasms of endothelial and B-cell origin. majority tumor cells in these malignancies are latently infected, latency genes consequently thought play a critical role virus-induced tumorigenesis. One such factor kshv-miR-K12-11, viral microRNA that constitutively expressed cell lines derived from KSHV-associated tumors, shares perfect homology its seed sequence with the cellular miR-155. Since miR-155...
Abstract SARS-CoV-2 is the causative agent of COVID-19 and a severe threat to global health. Patients infected with show wide range symptoms disease severity, while limited data available on its immunogenicity. Here, kinetics development SARS-CoV-2-specific antibody responses in relation clinical features dynamics specific B-cell populations are reported. Immunophenotyping B cells was performed by flow cytometry longitudinally collected PBMCs. In parallel, serum samples were analyzed for...
The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. S1 ELISA was found be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible (intra-assay coefficient variability (CV) 5.3%, inter-assay CV 7.9%). A...
The coronavirus SARS-CoV-2 is the causative agent for disease COVID-19. To capture IgA, IgG, and IgM antibody response of patients infected with at individual epitope resolution, we constructed planar microarrays 648 overlapping peptides that cover four major structural proteins S(pike), N(ucleocapsid), M(embrane), E(nvelope). arrays were incubated sera 67 positive 22 negative control samples. Specific responses to detectable, nine associated a more severe course disease. A random forest...
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must be activated by proteolytic cleavage into S1 S2. A recombinant modified vaccinia virus Ankara (MVA) expressing native, full-length S (MVA-SARS-2-S) currently under investigation candidate vaccine in phase I clinical studies. Initial results from immunogenicity monitoring revealed induction of S-specific antibodies binding to S2, but low-level antibody responses the domain. Follow-up investigations...
The Middle East respiratory syndrome (MERS) is a disease caused by MERS coronavirus (MERS-CoV). In follow up to phase 1 trial, we perform longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, neutralization capacity as well T B cell...
The clinical course of COVID-19 patients ranges from asymptomatic infection, via mild and moderate illness, to severe disease even fatal outcome. Biomarkers which enable an early prediction the severity progression, would be enormously beneficial guide patient care intervention prior hospitalization.Here we describe identification plasma protein biomarkers using antibody microarray-based approach in order predict a cause already phase SARS-CoV-2 infection. To this end, samples two...
Abstract In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine candidates, MVA-SARS-2-S MVA-SARS-2-ST, encoding native prefusion-stabilized SARS-CoV-2 spike protein, respectively. MVA-SARS-2-ST was more immunogenic than MVA-SARS-2-S, but both less compared...
ABSTRACT Background Invasive mould infections (IMI) cause substantial morbidity and mortality in populations at risk. Novel treatment approaches are urgently needed. Targeting immune checkpoints may reverse hyporesponsiveness of the innate adaptive systems. Methods In this prospective, observational study, we investigated checkpoint expression levels on cells patients with invasive aspergillosis (IA; n = 25) mucormycosis (MU; 7). Healthy controls (HC; 5) matched haematological diseases but...
The West African Ebola virus disease (EVD) outbreak was the largest EVD in history. However, data on lymphocyte dynamics and antigen specificity of T cells survivors are scarce, our understanding pathophysiology is limited. A case survival which patient cleared (EBOV) infection without experimental drugs allowed for detailed examination dynamics. We demonstrate persistence T-cell activation well beyond viral clearance detect EBOV-specific cells. Our study provides significant insights into...
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for development improved diagnostics, therapeutics, and vaccines. Here, we report longitudinal analysis three patients with moderate (#1) mild disease (#2 #3). Antibody serum responses were analyzed using spike glycoprotein enzyme linked immunosorbent assay (ELISA), full-proteome peptide, glycan microarrays. ELISA...
Abstract Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox and viral vector. MVA-MERS-S candidate Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive neutralizing antibodies were detectable in only single study participant after the first dose of vaccine, 3 10 second dose, third dose.
MicroRNAs (miRNAs) are small RNAs that regulate diverse biological processes including multiple aspects of the host-pathogen interface. Consequently, miRNAs commonly encoded by viruses undergo long-term persistent infection. Papillomaviruses (PVs) capable undergoing infection, but as yet, no widely-accepted PV-encoded have been described. The incomplete understanding is due in part to lack tractable laboratory models for most PV types. To overcome this, we developed miRNA Discovery forced...
In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen VSV-EBOV revealed safe and immunogenic profile demonstrated clinical efficacy. While EBOV-specific immune responses this candidate have previously been investigated, limited human data on immunity VSV vector are available. Within scope phase 1 study, we performed comprehensive longitudinal analysis adaptive internal...